Nikole Kimes Took the Scenic Route to the CEO’s Chair

Nikole Kimes’s career begins with a disagreement. She loved environmental science. She loved human biology. The usual academic menu treated those interests as separate entrees, and she suspected they belonged on the same plate. So she wandered. She earned a science degree, then a master’s in holistic health. She joined the Peace Corps and taught human health, environmental education and basic business principles. She returned to a laboratory and worked in neurobiology. Each stop was useful. None quite answered the question she was carrying.

Kimes has called that early route “a bit meandering,” which is both accurate and slightly unfair. The line only looks crooked if a job title is the unit of measurement. Follow the question instead and the shape becomes clearer: How does an environment influence a living system, and how does the system answer back?

At the Medical University of South Carolina, she found a doctoral program that let molecular and cellular biology share a room with environmental questions. Her subject was the coral microbiome. She studied how changing conditions altered microbial communities and, in turn, the health of an entire reef ecosystem. There was no single villain or solitary hero in that work. There were networks, dependencies and consequences. Systems biology gave her what she later called an “ah ha” moment: a language capacious enough to hold both of her old loves.

The question survives the scenery

After the PhD came postdoctoral work at the Belle W. Baruch Institute for Marine and Coastal Sciences, then research in Alicante, Spain. By then the microbiome revolution was changing the scale at which scientists described a human being. Kimes saw a bridge. The ecological logic she had learned in coral communities could be applied to microbial communities closer to home.

Her publication record from those years reads like an atlas of microbial consequence. One paper compared the functional structure of microbes in healthy and yellow-band-diseased Caribbean reef-building coral. Another examined how temperature regulates virulence factors in Vibrio coralliilyticus, a coral pathogen. She also co-authored a perspective on microbial transformation after the Deepwater Horizon oil spill. The subjects changed, but the habit stayed constant: look beyond a list of organisms and ask what the community is doing, what pressure is acting on it and how function changes when conditions move.

That distinction matters. A catalog tells you who is present. Ecology asks how presence becomes behavior. Kimes would later describe metabolomics in similar terms: a way to move beyond what potential exists toward which functions are actually being fulfilled. It is a patient mode of inquiry, suspicious of tidy answers and attentive to relationships. It also happens to be useful preparation for leading a startup, where an organization chart can tell you who is present but very little about how the company really works.

She and her family returned to San Francisco. Kimes deliberately went looking for a mentor in the human microbiome and found Susan Lynch at the University of California, San Francisco. Lynch’s lab approached the human microbiome as an ecological system and studied its relationship with immune development early in life. For Kimes, the intellectual fit was unusually exact. The wandering question had found its laboratory.

The work in Lynch’s lab became the translational foundation for Siolta Therapeutics. Lynch, Kimes and Khosla Ventures partner Samir Kaul formed the company in 2016. Kimes was an inventor of its underlying technology. She was also, at first, its only paid employee.

A CEO assembled in installments

Six months before the company conversation began, Kimes has said, she would have laughed if someone predicted she would start a biotech. Even after she did, she avoided calling herself its chief executive. Her first title was VP of R&D. Then she became chief scientific officer. Siolta still did not have a CEO.

The restraint was not coy. Kimes and Lynch agreed to revisit the leadership question at every stage. They expected the right person might change as the company changed. Meanwhile, Kimes was learning the work in front of her: licenses, intellectual property, accounting, financing, regulation, hiring and the thousand small translations required to move an academic idea toward a clinical program.

Bay Area life-science institutions, including MBC BioLabs and California Life Sciences, supplied community and practical instruction. Kimes asked questions about the things her scientific training had never needed to cover. She found mentors and advisors. The new subjects proved as compelling to her as the science. Eventually, the title became a description rather than an aspiration: she was already doing the CEO’s job.

One mentor was the late John Martin, the longtime Gilead leader. Kimes has said his experience with prevention helped Siolta think about the commercial case for intervening before a condition takes hold. Lynch remained the scientific co-founder and postdoctoral mentor. Kaul brought the venture perspective and a personal interest in the field. Around them grew a network of clinicians, scientists, board members and incubator colleagues. The popular picture of a founder is a singular figure with an unusually bright lightbulb. Kimes’s version has more people in it, which is both less cinematic and more believable.

The way she handled the title offers a second practical idea: leadership can be reviewed without being provisional. Kimes and Lynch’s repeated question about who should run the next stage did not weaken her authority. It tied authority to the company’s needs. Each review was a chance to separate attachment from fit. So far, their answer kept returning to the scientist who knew the technology, had learned the business and could translate between the two.

There is a pleasing inversion here. Founder stories are often edited backward, turning every childhood interest into foreshadowing and every decision into destiny. Kimes tells hers as a system: education, timing, mentors, capital, science and serendipity interacting. She did not always know the next node. She knew how to test it.

The ecologist’s operating manual

Kimes’s company-building advice sounds like it came from somebody who has watched neat diagrams collide with living systems. There is no single right path, she argues. Founders need an idea, determination and resources, but the route should fit the founder and the problem. Talk to people. Do the market research. Find excellent advisors. Hire a strong team. Protect the intellectual property. Choose investors who share the long view, not merely the term sheet within reach.

The phrase is irresistible coming from a microbiome scientist, but the useful word is “creating.” Kimes’s career has required conviction without the theatre of certainty. A scientist entering business has to admit what she does not know. A first-time CEO has to learn without making uncertainty everyone else’s burden. A founder working in a new therapeutic modality has to maintain a thesis while letting evidence revise the plan.

At Siolta, that meant building a lean team across microbiology, immunology, bioinformatics, clinical operations, diagnostics and manufacturing. The company developed its Precision Symbiotics platform around defined communities of naturally occurring microbes and advanced a lead program into clinical studies. Kimes also became chair of the Microbiome Therapeutics Innovation Group, an industry coalition working on standards and policy for microbiome-based products. The researcher who once looked for a field connecting ecosystems and human biology now operates at the junction of science, company-building and an emerging industry.

Even the company’s name carries the ecological thesis. Siolta, pronounced “sheel-ta,” comes from an Irish word for seeds. It is a compact metaphor for restoring a depleted microbial community with deliberately selected organisms. A conventional pharmaceutical story often begins with one target and one molecule. Siolta’s begins with a neighborhood. Kimes has consistently framed the technical challenge as an ecosystem problem that must still satisfy the exacting requirements of drug development. Complexity is not an excuse for vagueness. It is the reason to build better tools.

That posture also explains her interest in diagnostics and patient stratification. If biological systems vary across people and over time, then product design cannot end at making the intervention. The company has paired microbial data with bioinformatics and machine learning to identify patterns and inform who may respond. Kimes’s aspiration is broader than a single program: she has spoken about a future in which precision methods, earlier intervention and combinations of emerging modalities change how difficult biological problems are approached. It is an ecologist’s ambition expressed in the grammar of a drug developer.

A map drawn at the right scale

By 2024, Kimes had led a $12 million Series C financing, bringing Siolta’s disclosed funding to roughly $42 million. In 2026 interviews, she described a decade-long journey from academic scientist to the person navigating strategy, regulation, intellectual property and financing. She also spoke plainly about the stepwise approach: prove what can be proved, add the people a stage requires, and resist building machinery before the science can carry it.

That discipline is the quiet center of her story. It is easy to admire a bold thesis after it acquires a board, a pipeline and a financing history. More useful is the sequence that came before: Kimes kept asking what the evidence allowed next. She did not need to arrive in 2016 with the posture of a veteran pharmaceutical executive. She needed enough curiosity to learn tomorrow’s job and enough honesty to reconsider who should hold it.

A reef is a fine place to learn this lesson. Its order is distributed. Its strength comes from relationships. Change one condition and the whole arrangement responds. Kimes carried that habit of attention from South Carolina to Spain, from UCSF to San Carlos, and from the bench into the boardroom.

The scenic route, it turns out, was not a detour. It was the training.